Phase I study of Ro 31-7453 [R 440; MKC-1], a novel cell cycle inhibitor, administered as escalating oral doses in adults with solid tumors: 4-day schedule

Trial Profile

Phase I study of Ro 31-7453 [R 440; MKC-1], a novel cell cycle inhibitor, administered as escalating oral doses in adults with solid tumors: 4-day schedule

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs MKC 1 (Primary)
  • Indications Breast cancer; Colorectal cancer; Lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Dec 2009 Actual end date (Aug 2001) added as reported by ClinicalTrials.gov.
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top